跳转至内容
Merck
CN
  • Comparison of growth factor treatments on the fibrochondrogenic potential of canine fibroblast-like synoviocytes for meniscal tissue engineering.

Comparison of growth factor treatments on the fibrochondrogenic potential of canine fibroblast-like synoviocytes for meniscal tissue engineering.

Veterinary surgery : VS (2014-03-13)
Jason Spina, Jennifer Warnock, Katja Duesterdieck-Zellmer, Wendy Baltzer, Jesse Ott, Brian Bay
摘要

To determine the in vitro effects of differing growth factor treatments on the fibrochondrogenic potential of fibroblast-like synoviocytes from cruciate ligament deficient femorotibial joints of dogs. In vitro study. Synoviocytes from dogs (n = 8) with naturally occurring cruciate ligament insufficiency. Synoviocytes were cultured in monolayer and synthesized into tensioned synoviocyte bioscaffolds (TSB) suspended in media containing TGF-β3, or FGF-2, TGF-β1, and IGF-I. The 1,9-dimethylmethylene blue (DMMB) assay and toluidine blue stain assessed glycosaminoglycan content; hydroxyproline assay, and collagen I and II immunohistochemistry assessed collagen content. Biomechanical properties were determined by materials testing/force-deformation curves. All tissue cultures formed tensioned fibrous tissue-like constructs. Mean tissue cellularity and cellular viability was significantly greater in the triple growth factor-treated TSB by 0.09% and 44%, respectively. Percentage collagen content, and relative gene expression for collagen I, II, and aggrecan was not significantly different between groups. Median percentage of GAG content was significantly greater in triple growth factor-treated TSB by 1.6%. Biomechanical properties were not different in compression. Triple growth factor-treated TSB were significantly stronger in toughness, peak load to failure, and stiffness in tension. TGF-β3 cultured bioscaffolds failed to outperform triple growth factor-treated TSB. Architectural extracellular matrix (ECM) organization and cellularity likely explained the differences between groups. TGF-β3 alone cannot be recommended at this time for in vitro formation of autologous fibrocartilage bioscaffolds for meniscal deficiency.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
2-丙醇, suitable for HPLC, 99.9%
Sigma-Aldrich
2-丙醇, ACS reagent, ≥99.5%
Sigma-Aldrich
氯仿, contains 100-200 ppm amylenes as stabilizer, ≥99.5%
Sigma-Aldrich
氯仿, contains ethanol as stabilizer, ACS reagent, ≥99.8%
Sigma-Aldrich
2-丙醇, BioReagent, ≥99.5%, Molecular Biology
Sigma-Aldrich
异丙醇, meets USP testing specifications
Sigma-Aldrich
2-丙醇, HPLC Plus, for HPLC, GC, and residue analysis, 99.9%
Sigma-Aldrich
2-丙醇, anhydrous, 99.5%
Sigma-Aldrich
2-丙醇, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.8% (GC)
Sigma-Aldrich
2-丙醇, Laboratory Reagent, ≥99.5%
Sigma-Aldrich
氯仿, contains amylenes as stabilizer, ACS reagent, ≥99.8%
Sigma-Aldrich
异丙醇, ≥99.7%, FCC, FG
Sigma-Aldrich
2-丙醇, puriss. p.a., ACS reagent, ≥99.8% (GC)
Sigma-Aldrich
氯仿, ACS spectrophotometric grade, ≥99.8%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
2-丙醇, BioUltra, Molecular Biology, ≥99.5% (GC)
Sigma-Aldrich
氯仿, anhydrous, ≥99%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
氯仿, anhydrous, contains amylenes as stabilizer, ≥99%
Supelco
2-丙醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
2-丙醇, electronic grade, 99.999% trace metals basis
Sigma-Aldrich
钙黄绿素-AM, suitable for fluorescence, BioReagent, ≥90% (HPLC)
Sigma-Aldrich
2-丙醇, puriss., meets analytical specification of Ph. Eur., BP, USP, ≥99.5% (GC)
Supelco
2-丙醇, analytical standard
Sigma-Aldrich
2-丙醇, suitable for HPLC, 99.5%
USP
2-丙醇, United States Pharmacopeia (USP) Reference Standard
Supelco
氯仿, analytical standard
Sigma-Aldrich
钙黄绿素-AM, Small Package (20 X 50 μg ), ≥90.0% (HPLC)
Supelco
氯仿, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
氯仿, ≥99%, PCR Reagent, contains amylenes as stabilizer
Sigma-Aldrich
钙黄绿素AM 溶液, 4 mM in DMSO, ≥90% (HPLC), solution
Supelco
残留溶剂-氯仿, Pharmaceutical Secondary Standard; Certified Reference Material